A Precision Oncology Approach Calls for Regular ESR1 Monitoring
Emerging liquid biopsy techniques enable sensitive, routine monitoring of ESR1 mutations in metastatic HR+ breast cancer.
Emerging liquid biopsy techniques enable sensitive, routine monitoring of ESR1 mutations in metastatic HR+ breast cancer.
A researcher's new mouse model for studying breast cancer could enhance understanding of cancer metastasis and its spread to organs.
Bio-Rad Laboratories launched its first ultrasensitive multiplexed digital PCR assay, the ddPLEX ESR1 Mutation Detection Kit.Â
Though breast cancer rates for men are much lower, it is estimated that in 2023, about 2,800 men will be diagnosed with breast cancer.
Read MoreExai Bio’s liquid biopsy platform can detect breast cancer at the earliest stages and the smallest tumor sizes using a standard blood sample.Â
Read MoreDNADX utilizes sequencing DNA data from tumor tissue or plasma circulating tumor DNA to classify breast cancer into four subtypes or clusters.
Read MorePreciseBreast, an AI-powered digital morphology tool, has a fast turnaround time and is cost-effective compared to gene expression tests.
Read MoreInvitae announced the results of its study on universal hereditary cancer genetic testing in breast cancer patients in a rural population.
Read MoreBiocartis and APIS Assay Technologies are expanding their collaboration to include the commercialization of the APIS ESR1 Mutations Kit.
Read MoreThe findings suggest the need for continued monitoring of access to breast cancer screening and early diagnosis services.
Read MoreIbex launched an AI-powered solution that aids pathologists in setting a higher standard for accurate HER2 scoring in breast cancer patients.
Read MoreThis computational model makes it possible to predict the genetic risk of developing breast cancer based on genetic profiles.Â
Read MoreNew findings suggest that overdiagnosis may be common among older women who are diagnosed with breast cancer after screening.
Read MoreDevyser LynchFAP and Devyser BRCA PALB2 genetic test kits offer efficient, targeted analysis of genes associated with increased cancer risk.
Read MoreExai Bio is collaborating with Quantum Leap Healthcare Collaborative to broaden the use of its novel, RNA-based liquid biopsy platform.
Read MoreThe Centers for Medicare & Medicaid Services approved Advanced Diagnostic Laboratory Test status for PreludeDx’s DCISionRT test.
Read MoreNatera’s Signatera MRD test has met coverage requirements for adjuvant and recurrence monitoring in patients with breast cancer.
Read MorePreciseDx announced that the NYSDOH approved the PDxBr, an LDT designed to enrich breast cancer grading and improve risk categorization.
Read More